BC Innovations | Jun 13, 2018
Distillery Therapeutics


INDICATION: Lung cancer, sarcoma Cell culture studies suggest inhibiting IFT88 or SCLT1 could help treat kinase inhibitor-resistant lung cancer and rhabdomyosarcoma. In a human EGFR inhibitor-resistant non-small cell lung cancer (NSCLC) cell line, the EGFR...
BC Extra | Jun 7, 2018
Preclinical News

Targeting tumor cilia could reverse resistance to kinase inhibitors

A Cell Reports study from Institute of Cancer Research (ICR) researchers and colleagues identified cilia on tumor cells as a new, potentially universal target for sensitizing drug-resistant cells to kinase inhibitors. The research suggests inhibiting...
BC Innovations | Sep 17, 2009
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Basal cell carcinoma (BCC) Kinesin family member 3A (KIF3A); intraflagellar transport 88 homolog (IFT88) A study in mice and human tissue suggests that antagonizing...
Items per page:
1 - 3 of 3